Real world study in EGFR mutated unresectable nonsmall cell lung cancer patients.

Mutation testing,treatment patterns, and outcomes in EGFR mutated unresectable nonsmall cell lung cancer patients. A Retrospective Observational Study - LEROS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030230162

Enrollment

120

Registered

2023-06-24

Start date

2023-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer Solid tumors, Lung cancer, Non small cell lung cancer, Genetic mutation, EGFR

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Histologically and lab-confirmed diagnosis of stage III NSCLC -Histologically and lab-confirmed diagnosis of stage I-II NSCLC -Tumor harbors at least 1 of the 2 common EGFRms: Exon 19 deletion or L858R

Exclusion criteria

Exclusion criteria: -Evidence of other cancer diagnoses (apart from basal cell carcinoma) within one year prior to the index diagnosis date -Participated in an investigational clinical trial for the treatment of any cancer, including NSCLC, or any early access program from 2016 onward

Design outcomes

Primary

Measure	Time frame
rwPFS	—

Secondary

Measure	Time frame
-Demographic and clinical characteristics -Treatment patterns -Percentage of patients tested for mutations, testing methods and results -rwOS -rwTTNTD	—

Countries

Austria, France, Japan, Korea, Taiwan, United Kingdom, United States of America

Contacts

Public ContactAtsuko ICCC: Ono

3H Medi Solution Inc.

ono-atsuko@3h-ms.co.jp+81-80-3017-5063

Outcome results